文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

2021 年世卫组织中枢神经系统肿瘤分类:概述。

The 2021 WHO Classification of Tumors of the Central Nervous System: a summary.

机构信息

Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.

Department of Pathology, University of California San Francisco, San Francisco, California, USA.

出版信息

Neuro Oncol. 2021 Aug 2;23(8):1231-1251. doi: 10.1093/neuonc/noab106.


DOI:10.1093/neuonc/noab106
PMID:34185076
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8328013/
Abstract

The fifth edition of the WHO Classification of Tumors of the Central Nervous System (CNS), published in 2021, is the sixth version of the international standard for the classification of brain and spinal cord tumors. Building on the 2016 updated fourth edition and the work of the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy, the 2021 fifth edition introduces major changes that advance the role of molecular diagnostics in CNS tumor classification. At the same time, it remains wedded to other established approaches to tumor diagnosis such as histology and immunohistochemistry. In doing so, the fifth edition establishes some different approaches to both CNS tumor nomenclature and grading and it emphasizes the importance of integrated diagnoses and layered reports. New tumor types and subtypes are introduced, some based on novel diagnostic technologies such as DNA methylome profiling. The present review summarizes the major general changes in the 2021 fifth edition classification and the specific changes in each taxonomic category. It is hoped that this summary provides an overview to facilitate more in-depth exploration of the entire fifth edition of the WHO Classification of Tumors of the Central Nervous System.

摘要

世界卫生组织 2021 年发布的《中枢神经系统肿瘤分类》第五版是脑和脊髓肿瘤分类的国际标准第六版。该版在 2016 年更新的第四版和中枢神经系统肿瘤分类信息分子与实用方法联盟的工作基础上,引入了重大变革,推进了分子诊断在中枢神经系统肿瘤分类中的作用。同时,它仍然依赖于肿瘤诊断的其他既定方法,如组织学和免疫组织化学。这样,第五版为中枢神经系统肿瘤命名和分级制定了一些不同的方法,并强调了综合诊断和分层报告的重要性。新版引入了新的肿瘤类型和亚型,其中一些基于新的诊断技术,如 DNA 甲基化组谱分析。本文综述了 2021 年第五版分类中的主要总体变化以及每个分类类别的具体变化。希望这份总结能提供一个概述,方便更深入地探讨整个《世界卫生组织中枢神经系统肿瘤分类》第五版。

相似文献

[1]
The 2021 WHO Classification of Tumors of the Central Nervous System: a summary.

Neuro Oncol. 2021-8-2

[2]
[The 2021 WHO classification of tumours of the central nervous system].

Ann Pathol. 2022-10

[3]
World Health Organization Classification of Tumors of the Central Nervous System 5 Edition (WHO CNS5): What's new?

Indian J Pathol Microbiol. 2022-5

[4]
Pediatric CNS tumors and 2021 WHO classification: what do oncologists need from pathologists?

Front Mol Neurosci. 2024-3-13

[5]
Classification and Grading of Central Nervous System Tumors According to the World Health Organization 5th Edition.

Semin Neurol. 2023-12

[6]
[The 2021 WHO Classification of Tumors, 5th edition, Central Nervous System Tumors: A Short Review].

Brain Nerve. 2022-6

[7]
Major Changes in 2021 World Health Organization Classification of Central Nervous System Tumors.

Radiographics. 2022

[8]
What Changed in CNS5? A Mini-Review on General Changes and Adult Diffuse Gliomas.

Ann Afr Med. 2024-7-1

[9]
The World Health Organization Classification of Tumors of the Central Nervous System, Fifth Edition, 2021: A Critical Analysis.

Adv Tech Stand Neurosurg. 2023

[10]
The WHO 2021 Classification of Central Nervous System tumours: a practical update on what neurosurgeons need to know-a minireview.

Acta Neurochir (Wien). 2022-9

引用本文的文献

[1]
Estimating Health State Utilities for IDH-Mutant Diffuse Glioma.

Pharmacoecon Open. 2025-9-6

[2]
Molecularly matched targeted therapies plus radiotherapy in glioblastoma: the phase 1/2a NM umbrella trial.

Nat Med. 2025-9-5

[3]
Conserved methylation signature accurately predicts heavily irradiated CNS tumour with perplexing histopathology: A case report.

Biomed Rep. 2025-8-14

[4]
NUTM2A-AS1 as a potential key regulator in cancer: unraveling its ceRNA networks and impact on tumor biology.

Eur J Med Res. 2025-9-3

[5]
Combined inhibition of SHP2 overcomes adaptive resistance to type 1 BRAF inhibitors in BRAF V600E-driven high-grade glioma.

Neurooncol Adv. 2025-8-2

[6]
Progenitor cells, microglia, and non-coding RNAs: Orchestrators of glioblastoma pathogenesis and therapeutic resistance.

Noncoding RNA Res. 2025-8-5

[7]
A Rare Case of Bilateral Lateral Ventricular Subependymomas With Complete Resection of the Residual Tumor via Flexible Neuroendoscopy 20 Years After Initial Surgery.

Cureus. 2025-7-29

[8]
Neurocognitive evaluation in patients with intracranial Meningiomas: A systematic review.

Brain Spine. 2025-8-6

[9]
Deregulating m6A regulators leads to altered RNA biology in glioma cell lines.

bioRxiv. 2025-8-19

[10]
SHH Pathway Inhibition and Astrocyte Co-culture Induce Distinct Responses in Glioblastoma and Cancer Stem Cells.

Res Sq. 2025-8-19

本文引用的文献

[1]
Re: International System for Human Cytogenetic or Cytogenomic Nomenclature (ISCN): Some Thoughts, by T. Liehr.

Cytogenet Genome Res. 2021

[2]
A subset of pediatric-type thalamic gliomas share a distinct DNA methylation profile, H3K27me3 loss and frequent alteration of EGFR.

Neuro Oncol. 2021-1-30

[3]
Guidelines for human gene nomenclature.

Nat Genet. 2020-8

[4]
CDKN2A/B homozygous deletion is associated with early recurrence in meningiomas.

Acta Neuropathol. 2020-9

[5]
cIMPACT-NOW update 7: advancing the molecular classification of ependymal tumors.

Brain Pathol. 2020-9

[6]
Prognostic Value of Histopathological Features and Loss of H3K27me3 Immunolabeling in Anaplastic Meningioma: A Multicenter Retrospective Study.

J Neuropathol Exp Neurol. 2020-7-1

[7]
A polyphenotypic malignant paediatric brain tumour presenting a MN1-PATZ1 fusion, no epigenetic similarities with CNS High-Grade Neuroepithelial Tumour with MN1 Alteration (CNS HGNET-MN1) and related to PATZ1-fused sarcomas.

Neuropathol Appl Neurobiol. 2020-8

[8]
Genomics Paves the Way for Better Infant Medulloblastoma Therapy.

J Clin Oncol. 2020-6-20

[9]
Nonmetastatic Medulloblastoma of Early Childhood: Results From the Prospective Clinical Trial HIT-2000 and An Extended Validation Cohort.

J Clin Oncol. 2020-6-20

[10]
cIMPACT-NOW update 6: new entity and diagnostic principle recommendations of the cIMPACT-Utrecht meeting on future CNS tumor classification and grading.

Brain Pathol. 2020-7

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索